Plasminogen activator inhibitor-1 level associated with the components of metabolic syndrome in a 4G/5G polymorphism dependent manner

Lőrincz, Hajnalka; Galgóczy, E.; Katkó, M.; Ratku, Balázs; Ötvös, T.; Harangi, M.; Paragh, G.; Szabó, Z.; Somodi, Sándor

doi:10.1016/j.atherosclerosis.2022.06.705

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, previous studies suggested that very-low density lipoprotein (VLDL) was capable of increasing the PAI-1 level via a VLDL response element localized in the promoter region of the PAI-1 gene, mediating VLDL-induced PAI-1 transcription in endothelial cells [ 40 , 41 ]. In a recent pilot study [ 42 ], the genotype distribution of PAI-1 4G/5G polymorphism did not significantly differ in NDO individuals compared to normal-weight controls. There were correlations between PAI-1 levels and the components of metabolic syndrome suggesting a closer link between PAI-1 and lipid as well as carbohydrate metabolism in subjects with 5G/5G genotype.…”

Section: Role Of Novel Adipokines In Non-diabetic Obesitymentioning

confidence: 99%

Crucial Regulatory Role of Organokines in Relation to Metabolic Changes in Non-Diabetic Obesity

et al. 2023

View full text Add to dashboard Cite

Obesity is characterized by an excessive accumulation of fat leading to a plethora of medical complications, including coronary artery disease, hypertension, type 2 diabetes mellitus or impaired glucose tolerance and dyslipidemia. Formerly, several physiological roles of organokines, including adipokines, hepatokines, myokines and gut hormones have been described in obesity, especially in the regulation of glucose and lipid metabolism, insulin sensitivity, oxidative stress, and low-grade inflammation. The canonical effect of these biologically active peptides and proteins may serve as an intermediate regulatory level that connects the central nervous system and the endocrine, autocrine, and paracrine actions of organs responsible for metabolic and inflammatory processes. Better understanding of the function of this delicately tuned network may provide an explanation for the wide range of obesity phenotypes with remarkable inter-individual differences regarding comorbidities and therapeutic responses. The aim of this review is to demonstrate the role of organokines in the lipid and glucose metabolism focusing on the obese non-diabetic subgroup. We also discuss the latest findings about sarcopenic obesity, which has recently become one of the most relevant metabolic disturbances in the aging population.

show abstract

Section: Role Of Novel Adipokines In Non-diabetic Obesitymentioning

confidence: 99%